Submitted protocols are reviewed by both the Clinical Protocol Review Committee (LSU SVM Department of Veterinary Clinical Sciences) and LSU’s Institutional Animal and Care Use Committee (IACUC) with the intent to ensure that welfare and confidentiality matters are observed. These reviews are patterned on “Good Clinical Practices” for conduct of clinical trials in human medicine.
FURTHER INFORMATION ON GOOD CLINICAL PRACTICES
This trial consists of osteopathic treatments combined with DA2P (distemper, adenovirus type-2, and parvovirus) vaccine.
Osteopathy is a holistic and manual therapy that aims to rebalance all structures in the body, making it more efficient. It is a very popular preventive and palliative therapy for humans and animals in Europe.
Our research aims to determine if osteopathic manipulation can boost the puppies’ specific defense when combined with classic administration of DA2P vaccine.
Puppies will need to be brought in every 3 weeks for vaccine boosters and one last visit 4 weeks after the last vaccine for a total of 5 visits over 91 days.
Nancy Welborn, DVM (LSU 1990), Associate Professor of Community Practice
Anais Musso, AO, Clinical Instructor of Animal Osteopathy
Have you seen a cat with goopy eyes recently? The Lewin Lab for Innovative Eye Research is currently searching for cats with ocular Feline Herpes Virus (FHV-1) for clinical trials. The trial is to test a new drug treatment modality for FHV-1.
We have developed a novel slow-release ocular implant that contains a well-known and commonly used antiviral drug. The purpose of this clinical trial is to test the efficacy and tolerability of this implant in cats with the feline herpes virus. Enrolled animals will receive either the ocular implant under general anesthesia or eye drops containing antiviral medications. All animals will receive topical ophthalmic antibiotics as well. Outcomes will be assessed using eye examinations, amount of virus shed and owner satisfaction surveys over a 90-day period.
FHV-1 will be confirmed or excluded during the first examination at LSU.
Prior testing does not have to have been performed at your clinic.
The patient must have ocular diseases consistent with FHV-1.
The patient must weigh over 1kg.
The patient must not have severe concurrent systemic disease.
The owner must agree to all of the study conditions listed in the protocol.
The owner is responsible for paying the initial LSU Ophthalmology Service examination fee of $178.50.
If eligible, pets will receive the following items free of charge.
If eligible, the pet will receive testing and treatment for FHV-1 at a minimal cost
to the owner
The pet’s participation in this study will aid in scientific advancement to develop
a new antiviral implant to treat FHV-1, which could help thousands of animals in the
future.
If you are interested in participating in this clinical trial, please contact us at the information below for further consideration:
Dr. Erinn Mills
LSU Small Animal Clinic
(225)-578-9600
